NCT03343587View on ClinicalTrials.gov

A Study of LY3375880 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 17, 2017

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions
Healthy
Interventions
DRUG

LY3375880 IV

administered IV

DRUG

LY3375880 SC

administered SC

DRUG

Placebo IV

administered IV

DRUG

Placebo SC

administered SC

Trial Locations (1)

91206

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03343587 - A Study of LY3375880 in Healthy Participants | Biotech Hunter | Biotech Hunter